These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39300963)

  • 1. Psychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes.
    MacLeish SA; Hood KK; Polonsky WH; Wood JR; Bode BW; Forlenza GP; Laffel LM; Buckingham BA; Criego AB; Schoelwer MJ; DeSalvo DJ; Sherr JL; Hansen DW; Conroy LR; Huyett LM; Vienneau TE; Ly TT;
    Diabetes Obes Metab; 2024 Dec; 26(12):5569-5579. PubMed ID: 39300963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod® 5 System.
    Polonsky WH; Hood KK; Levy CJ; MacLeish SA; Hirsch IB; Brown SA; Bode BW; Carlson AL; Shah VN; Weinstock RS; Bhargava A; Jones TC; Aleppo G; Mehta SN; Laffel LM; Forlenza GP; Sherr JL; Huyett LM; Vienneau TE; Ly TT;
    Diabetes Res Clin Pract; 2022 Aug; 190():109998. PubMed ID: 35853530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sleep and diabetes-specific psycho-behavioral outcomes of a new automated insulin delivery system in young children with type 1 diabetes and their parents.
    Bisio A; Brown SA; McFadden R; Pajewski M; Yu PL; DeBoer M; Schoelwer MJ; Bonner HG; Wakeman CA; Cherñavvsky DR; Gonder-Frederick L
    Pediatr Diabetes; 2021 May; 22(3):495-502. PubMed ID: 33289242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the Omnipod
    Polonsky WH; Hessler D; Layne JE; Zisser H
    Diabetes Technol Ther; 2016 Oct; 18(10):664-670. PubMed ID: 27673352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Satisfaction With Omnipod DASH in Adults With Type 1 Diabetes: A Nonblinded 1:1 Randomized Controlled Trial.
    Kong YW; Yuan CY; Kiburg K; Brown K; Trawley S; Partovi A; Roem K; Pham C; Harrison N; Fourlanos S; Ekinci EI; O'Neal DN
    J Clin Endocrinol Metab; 2024 Jul; 109(8):1984-1995. PubMed ID: 38373265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod
    DeSalvo DJ; Bode BW; Forlenza GP; Laffel LM; Buckingham BA; Criego AB; Schoelwer M; MacLeish SA; Sherr JL; Hansen DW; Ly TT
    Diabetes Technol Ther; 2024 Jun; 26(6):383-393. PubMed ID: 38277156
    [No Abstract]   [Full Text] [Related]  

  • 7. The psychosocial outcomes of advanced hybrid closed-loop system in children and adolescents with type 1 diabetes.
    Jalilova A; Pilan BŞ; Demir G; Özbaran B; Balkı HG; Arslan E; Köse SG; Özen S; Darcan Ş; Gökşen D
    Eur J Pediatr; 2024 Jul; 183(7):3095-3103. PubMed ID: 38661816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of predicted low suspend pump treatment on improving glycaemic control and quality of sleep in children with type 1 diabetes and their caregivers: the QUEST randomized crossover study.
    Schierloh U; Aguayo GA; Fichelle M; De Melo Dias C; Celebic A; Vaillant M; Barnard K; Cohen O; de Beaufort C
    Trials; 2018 Dec; 19(1):665. PubMed ID: 30509293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychosocial Outcomes Among Users and Nonusers of Open-Source Automated Insulin Delivery Systems: Multinational Survey of Adults With Type 1 Diabetes.
    Schipp J; Hendrieckx C; Braune K; Knoll C; O'Donnell S; Ballhausen H; Cleal B; Wäldchen M; Lewis DM; Gajewska KA; Skinner TC; Speight J
    J Med Internet Res; 2023 Dec; 25():e44002. PubMed ID: 38096018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes.
    Criego AB; Carlson AL; Brown SA; Forlenza GP; Bode BW; Levy CJ; Hansen DW; Hirsch IB; Bergenstal RM; Sherr JL; Mehta SN; Laffel LM; Shah VN; Bhargava A; Weinstock RS; MacLeish SA; DeSalvo DJ; Jones TC; Aleppo G; Buckingham BA; Ly TT
    Diabetes Technol Ther; 2024 Jan; 26(1):11-23. PubMed ID: 37850941
    [No Abstract]   [Full Text] [Related]  

  • 11. Patient perceptions of using the OmniPod system compared with conventional insulin pumps in young adults with type 1 diabetes.
    Lebenthal Y; Lazar L; Benzaquen H; Shalitin S; Phillip M
    Diabetes Technol Ther; 2012 May; 14(5):411-7. PubMed ID: 22283640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Evidence of Omnipod
    Forlenza GP; DeSalvo DJ; Aleppo G; Wilmot EG; Berget C; Huyett LM; Hadjiyianni I; Méndez JJ; Conroy LR; Ly TT; Sherr JL
    Diabetes Technol Ther; 2024 Aug; 26(8):514-525. PubMed ID: 38375861
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term assessment of the NHS hybrid closed-loop real-world study on glycaemic outcomes, time-in-range, and quality of life in children and young people with type 1 diabetes.
    Ng SM; Wright NP; Yardley D; Campbell F; Randell T; Trevelyan N; Ghatak A; Hindmarsh PC
    BMC Med; 2024 Apr; 22(1):175. PubMed ID: 38659016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
    Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
    Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions.
    Sherr JL; Buckingham BA; Forlenza GP; Galderisi A; Ekhlaspour L; Wadwa RP; Carria L; Hsu L; Berget C; Peyser TA; Lee JB; O'Connor J; Dumais B; Huyett LM; Layne JE; Ly TT
    Diabetes Technol Ther; 2020 Mar; 22(3):174-184. PubMed ID: 31596130
    [No Abstract]   [Full Text] [Related]  

  • 16. Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trial.
    Rubin RR; Peyrot M;
    Diabetes Technol Ther; 2012 Feb; 14(2):143-51. PubMed ID: 22133037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States.
    Biskupiak JE; Ramos M; Levy CJ; Forlenza G; Hopley C; Boyd J; Swift D; Lamotte M; Brixner DI
    J Manag Care Spec Pharm; 2023 Jul; 29(7):807-817. PubMed ID: 37133431
    [No Abstract]   [Full Text] [Related]  

  • 18. Satisfaction with the Use of Different Technologies for Insulin Delivery and Glucose Monitoring Among Adults with Long-Standing Type 1 Diabetes and Problematic Hypoglycemia: 2-Year Follow-Up in the HypoCOMPaSS Randomized Clinical Trial.
    Speight J; Holmes-Truscott E; Little SA; Leelarathna L; Walkinshaw E; Tan HK; Bowes A; Kerr D; Flanagan D; Heller SR; Evans ML; Shaw JAM
    Diabetes Technol Ther; 2019 Nov; 21(11):619-626. PubMed ID: 31335201
    [No Abstract]   [Full Text] [Related]  

  • 19. Satisfaction with continuous glucose monitoring is associated with quality of life in young people with type 1 diabetes regardless of metabolic control and treatment type.
    Franceschi R; Pertile R; Marigliano M; Mozzillo E; Maffeis C; Morotti E; Di Candia F; Fedi L; Iafusco D; Zanfardino A; Cauvin V; Maltoni G; Zucchini S; Cherubini V; Tiberi V; Minuto N; Bassi M; Rabbone I; Savastio S; Tinti D; Tornese G; Schiaffini R; Passanisi S; Lombardo F; Bonfanti R; Scaramuzza A; Troncone A
    Diabet Med; 2024 Jun; 41(6):e15307. PubMed ID: 38383984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of OMNIPOD® on the quality of life of adolescents with type 1 diabetes.
    Nivet E; Lo G; Nivot-Adamiak S; Guitteny MA; De Kerdanet M
    Arch Pediatr; 2022 Jan; 29(1):21-26. PubMed ID: 34753634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.